In one study, patients with MDS were divided into three groups according to their TP53 VAF; this study showed that patients who had TP53 VAF > 40% had inferior survival compared with patients with TP53 VAF < 20%, concluding that VAF is an essential factor for MDS prognosis [19]. The gene discussed is TP53; the disease is myelodysplastic syndrome.